What's Happening?
bioAffinity Technologies, Inc. has launched a pilot study in collaboration with Brooke Army Medical Center to explore the use of its CyPath Lung technology for diagnosing and treating asthma and chronic obstructive pulmonary disease (COPD). The study aims
to identify specific inflammatory biomarkers using flow cytometry and artificial intelligence, potentially leading to precision diagnostics and treatments. The research will involve approximately 40 participants, including patients with asthma, COPD, and a healthy control group. This initiative builds on bioAffinity's existing research pipeline and seeks to address the $92 billion asthma and COPD treatment market.
Why It's Important?
This study represents a significant step towards personalized medicine in respiratory care, particularly for conditions like asthma and COPD, which affect millions globally. By identifying specific biomarkers, bioAffinity aims to tailor treatments to individual patients, potentially improving outcomes and reducing healthcare costs. The collaboration with a major military medical center underscores the importance of this research in enhancing the health and readiness of military personnel, who may face unique respiratory challenges. Success in this study could lead to broader applications of CyPath technology, impacting both civilian and military healthcare sectors.
